Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–48.

Article  PubMed  CAS  Google Scholar 

Cote J, Leblanc R, Chu MP, McCurdy A, Masih-Khan E, Kardjadj M, et al. Real-world results of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database. Blood. 2022;140(Supplement 1):289–91.

Article  Google Scholar 

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124(20):3043–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Zangari M, et al. Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. J Clin Oncol. 2023;41(16suppl):8059–8059.

Article  Google Scholar 

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ra K, Ma G, Te W, Ja L, Mq L. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2023;78(1):21–33. https://doi.org/10.4065/78.1.21.

Article  Google Scholar 

Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol. 2005;75(5):370–5.

Article  PubMed  Google Scholar 

Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–7.

Article  PubMed  PubMed Central  Google Scholar 

Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169(6):851–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98(10):1540–9.

Article  PubMed  Google Scholar 

Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96(1):73–80.

Article  PubMed  Google Scholar 

Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195–200.

Article  PubMed  CAS  Google Scholar 

Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia. 2015;29(5):1195–201.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5(3):e296.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20.

Article  PubMed  Google Scholar 

D’Anastasi M, Notohamiprodjo M, Schmidt GP, Dürr HR, Reiser MF, Baur-Melnyk A. Tumor load in patients with multiple myeloma: β2-Microglobulin levels Versus whole-body MRI. Am J Roentgenol. 2014;203(4):854–62.

Article  Google Scholar 

Inker LA, Tighiouart H, Coresh J, Foster MC, Anderson AH, Beck GJ, et al. GFR Estimation using β-Trace protein and β2-Microglobulin in CKD. Am J Kidney Dis off J Natl Kidney Found. 2016;67(1):40–8.

Article  CAS  Google Scholar 

Lin G, Hari P, Chhabra S, Hamadani M, D’Souza A, Szabo A, et al. The significance of beta-II microglobulin (β2M) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) With renal impairment (RI). J Clin Oncol. 2020;38(15suppl):8544–8544.

Article  Google Scholar 

Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for Drug Resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931–5.

Article  PubMed  CAS  Google Scholar 

Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010;85(2):114–9.

Article  PubMed  Google Scholar 

Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):1–5.

Article  Google Scholar 

Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Morè S, Corradini P, et al. High levels of circulating Tumor plasma cells as a key Hallmark of Aggressive Disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(27):3120–31.

Article  PubMed  CAS  Google Scholar 

Garcés JJ, Termini R, Martín-Sánchez E, Lasa M, Perez JJ, Gutierrez NC, et al. Biological and clinical significance of undetectable circulating tumor cells (CTCs) in patients (pts) with multiple myeloma (MM). Blood. 2023;142(Supplement 1):646.

Article  Google Scholar 

Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132(1):59–66.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer. 2011;117(5):1001–9.

Article  PubMed  Google Scholar 

Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood. 2003;101(10):3849–56.

Article  PubMed  CAS  Google Scholar 

Crabtree M, Cai J, Qing X. Conventional karyotyping and fluorescence in situ hybridization for detection of chromosomal abnormalities in multiple myeloma. J Hematol. 2022;11(3):87–91.

Article